By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk’s shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker’s experimental obesity pill monlunabant came in below market expectations. The company announced headline results from its trial of monlunabant, an experimental drug it acquired as part of its…
(Reuters) -The U.S. Food and Drug Administration has approved Zevra Therapeutics’ drug for a rare and fatal genetic disorder, making it the first treatment to get a nod for the condition, the health regulator said on Friday. The company has been trying for years to bring the drug to market after the FDA previously declined…
By Juveria Tabassum, Nicholas P. Brown (Reuters) -Nike said on Thursday that former senior executive Elliott Hill will rejoin the company to succeed John Donahoe as president and CEO, as the sportswear giant shakes up its leadership amid efforts to revive sales and battle rising competition. The company’s shares rose 8% in after-hours trading. Hill…
(Reuters) – The U.S. Federal Reserve’s watered-down version of a landmark bank capital proposal is facing resistance from the Federal Deposit Insurance Corporation, a top banking regulator, Bloomberg News reported on Friday. At least three of five FDIC directors oppose the latest overhaul, the report said, citing people familiar with their thinking. The report points…
